I’m so excited about the launch of ESMFold2, ESMC, and the new ESM Atlas. This was a massive team effort, and I’m grateful to have worked with such an incredible group
@biohub.
A headline result I’m especially excited about: ESMFold2 can design minibinders and antibodies with nanomolar affinity, target selectivity, and functional activity against therapeutically relevant targets.
Today, we’re sharing the full binder design protocol.